GLUE · Monte Rosa Therapeutics, Inc.
$15.50
-0.34 (-2.15%)
At close · Aug 14
Market Cap
$1.32B
Shares
85.31M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$15.50
Open$15.72
Day$15.37–15.83
52W close$4.35–25.31
Avg vol 30d1.4M
Short int16.5M · 19.3% float · 10.6d
Short vol38%
Last earningsMar 20, 2025
DataJun 2021–Aug 2026
Filing10-Q · Aug 6
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−16%
below
Price vs 50-day avg
−23%
below
RSI (14)
31
neutral
MACD trend
Negative
52-week position
53%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−37%
trailing
6-month return
−21%
trailing
YTD return
−1%
this year
Relative strength
−34%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $20 › 200d $18 — 50d above 200d
Institutional flow
Distributing
-1% holders QoQ · +28 funds added
Insider flow
Distributing
Net -$631.4K over 90 days · 100% sells
Short interest
Falling
19.29% of float · ▼ -4.3% MoM · 10.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
191 holders — near 3-yr high, broad support
Squeeze score
64
elevated · 0–100
Fundamentals
Revenue growth
+64%
Y/Y
Free cash flow
$-27.5M
Balance sheet
$129.9M
net cash
Quant / Vol
risk profile
Volatility
96%
annualized · 1-yr
Max drawdown
−42%
past year
ATR
8.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−16%
Bearish
Price vs 50-day avg
−23%
Bearish
RSI (14)
31
Neutral
MACD trend
Negative
Bearish
52-week position
53%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $20 › 200d $18 — 50d above 200d
Institutional flow
Distributing
-1% holders QoQ · +28 funds added
Insider flow
Distributing
Net -$631.4K over 90 days · 100% sells
Short interest
Falling
19.29% of float · ▼ -4.3% MoM · 10.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
191 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $4
Now $16 · 53%
Range high $25
vs 200-day avg -16%
vs 50-day avg -23%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GLUE
this stock
Monte Rosa Therapeutics, Inc.
|
$1.32B | -1.1% | +63.5% | — | 19.3% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GLUE | -2.4% | -36.9% | -20.6% | -6.2% | -1.2% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -2.8% | -41.3% | -34.3% | -10.1% | -15.0% |
Key facts
CIK
1826457
CUSIP
61225M102
13F (30d)
188 filings
184 filers
Visit website
Investor relations